5 Key Takeaways
-
1
AAVantgarde Bio is developing gene therapies for inherited retinal diseases, with clinical programs for Usher syndrome type 1B and Stargardt disease.
-
2
The LUCE-1 phase 1/2 trial evaluates dual AAV DNA-splicing therapy for retinitis pigmentosa caused by MYO7A mutations in Usher syndrome type 1B.
-
3
Fifteen participants have been treated in LUCE-1, with no serious adverse events or dose-limiting toxicities reported.
-
4
No participants have withdrawn, and the company reported that immunosuppression is working well.
-
5
Early efficacy signals included improvements in best-corrected and low-luminance visual acuity, with gains of at least 3 lines in low-luminance visual acuity.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







